Abstract | AIM: METHODS: RESULTS: After 1 year of treatment, 22 patients (78.6%) reported an improvement in symptoms. The mean duration of menstruation were 18 and 5 days before and after treatment, respectively. No uterine perforations or pelvic inflammatory diseases occurred during or after the insertion procedures. Eighteen (64.3%) patients did not experience any adverse events, and the patients with adverse events reported that they could be managed by adjusting their medications or observation. CONCLUSION:
Levonorgestrel intrauterine system may have a role in the safe and effective management of intermenstrual spotting in patients with PCDSs.
|
Authors | Yu-Che Ou, Ying-Yi Chen, Kuo-Chung Lan, Ching-Chang Tsai, Li-Ching Chu, Ling-Yun Cheng |
Journal | The journal of obstetrics and gynaecology research
(J Obstet Gynaecol Res)
Vol. 48
Issue 1
Pg. 155-160
(Jan 2022)
ISSN: 1447-0756 [Electronic] Australia |
PMID | 34734462
(Publication Type: Journal Article)
|
Copyright | © 2021 Japan Society of Obstetrics and Gynecology. |
Chemical References |
|
Topics |
- Cicatrix
- Female
- Humans
- Intrauterine Devices, Medicated
(adverse effects)
- Levonorgestrel
(adverse effects)
- Metrorrhagia
- Pregnancy
- Retrospective Studies
|